Cantor Fitzgerald Initiates Coverage On Aquestive Therapeutics with Overweight Rating, Announces Price Target of $17
AQUESTIVE THERAPEUTICS, INC. +0.97% Pre
AQUESTIVE THERAPEUTICS, INC. AQST | 3.11 3.11 | +0.97% 0.00% Pre |
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Aquestive Therapeutics (NASDAQ:
AQST) with a Overweight rating and announces Price Target of $17.